Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

3.970 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Monday's pre-market session: top gainers and losers
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Agenus Posts 48% Q2 Revenue Miss
Via The Motley Fool
Examining the Future: Agenus's Earnings Outlook
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Earnings Scheduled For May 12, 2025
 
Via Benzinga
Agenus's Earnings: A Preview
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Insights Ahead: Agenus's Quarterly Earnings
 
Via Benzinga
Earnings Scheduled For August 11, 2025
 
Via Benzinga
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang
Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO presence and securing rights to key cancer drug manufacturing. 
Via Benzinga
Agenus Stock Is Trading Higher Tuesday: What's Going On?
Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and Balstilimab. 
Via Benzinga
Tuesday's pre-market session: top gainers and losers
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Here are the top movers in Tuesday's session.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Agenus (AGEN) Q4 2024 Earnings Call Transcript
AGEN earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development
Agenus secures a $22M mortgage and announces a strategic realignment to focus on botensilimab/balstilimab in MSS colorectal cancer. 
Via Benzinga
Earnings Scheduled For March 11, 2025
 
Via Benzinga
Agenus (AGEN) Q3 2024 Earnings Call Transcript
AGEN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The... 
Via Benzinga
Agenus (AGEN) Q2 2024 Earnings Call Transcript
AGEN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q2 2024
AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy... 
Via Benzinga
Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity
Agenus faces a setback as the FDA advises against accelerated approval for its immunotherapy combination, botensilimab and balstilimab, for relapsed/refractory microsatellite-stable colorectal cancer.... 
Via Benzinga
Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views
 
Via Benzinga
Topics Earnings
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
Dow Dips 250 Points; US Weekly Jobless Claims Surge
 
Via Benzinga
Topics Stocks
WBD Stock Pops as Warner Bros. Considers Streaming Spinoff
Warner Bros. stock is rising on Thursday as reports about a potential spinoff of its streaming division embolden WBD investors. 
Via InvestorPlace
Agenus Loses More Than 50% Value On Thursday - Here's Why
Agenus shares drop amid FDA's feedback on its immunotherapy combo botensilimab and balstilimab for colorectal cancer. The FDA advised against accelerated approval, citing concerns about survival... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.